GHM Chikungunya IgG/IgM Rapid Test US – Dual-Target Qualitative Detection of Chikungunya Virus IgG & IgM Antibodies with 15-Minute Results, Whole Blood / Serum / Plasma Sample Compatibility, and Professional Point-of-Care Use

SKU: GHM Chikungunya IgG/IgM Rapid Test US
Brand: Global Healthcare Medical

Product Overview

Global Healthcare Medical GHM Chikungunya IgG/IgM Rapid Test US is a lateral flow immunochromatographic assay designed for the qualitative detection and differentiation of IgG and IgM antibodies to chikungunya virus (CHIKV) in human whole blood, serum, or plasma specimens. The kit is intended for use by healthcare professionals as a screening test and as an aid in the diagnosis of chikungunya virus infection.

Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus (CHIKV), an RNA virus belonging to the Alphavirus genus of the Togaviridae family. The virus is transmitted to humans primarily through the bites of infected Aedes aegypti and Aedes albopictus mosquitoes. Chikungunya typically presents with sudden onset of fever and severe joint pain, often accompanied by muscle pain, headache, nausea, fatigue, and rash. While the acute phase of infection generally resolves within one to two weeks, a substantial proportion of patients experience chronic arthralgia that can persist for months or even years, accounting for 54% of the total chikungunya burden.

The global burden of chikungunya has escalated dramatically in recent years. In 2025, a resurgence of chikungunya virus disease was noted in multiple countries, with 445,271 suspected and confirmed cases and 155 deaths reported globally from 40 countries between 1 January and 30 September 2025. Prior to 2025, autochthonous transmission had been reported from 119 countries and territories across six WHO regions. The potential for further geographic spread remains significant due to the expanded distribution of Aedes mosquitoes, climate change, increased human mobility, and gaps in surveillance and diagnostic capacity. Early detection of cases and timely access to appropriate medical care are essential for minimizing clinical complications and reducing mortality.

The clinical presentation of chikungunya overlaps significantly with other arboviral diseases such as dengue, Zika, and yellow fever, making laboratory confirmation essential for accurate diagnosis. Because commercial immunochromatographic test kits for CHIKV remain scarce, rapid point-of-care testing plays a critical role in decentralizing diagnosis and improving access to testing at lower healthcare system levels.

The GHM Chikungunya IgG/IgM Rapid Test US delivers qualitative results in just 15 minutes, supporting rapid clinical decision-making at the point of care. The test is compatible with whole blood (venipuncture or fingerstick), serum, and plasma specimens, providing flexible sample collection options suitable for a wide range of clinical settings, including decentralized and resource-limited environments where laboratory infrastructure may be limited.

The kit is intended for in vitro diagnostic use and professional use only, suitable for application scenarios including physician office laboratories, hospital laboratories, public health screening programs in endemic areas, travel medicine clinics, and clinical laboratories. The VivaDiag product line is manufactured under an EN ISO 13485 certified quality management system covering in vitro diagnostic test kits and analyzers based on immunochromatography.

Key Features & Benefits

2-in-1 Detection – IgG and IgM in One Test

The GHM Chikungunya IgG/IgM Rapid Test US utilizes a lateral flow immunochromatographic assay capable of simultaneously detecting and differentiating chikungunya virus IgG and IgM antibodies from a single patient sample. The test incorporates two separate test lines: T1 for IgG and T2 for IgM, enabling clear differentiation between acute/recent infection and past infection or immunity in a single assay. This dual-target design provides a comprehensive diagnostic picture that supports appropriate clinical decision-making and effective patient management.

Fast Results – 15 Minutes

The GHM Chikungunya IgG/IgM Rapid Test US provides qualitative results in just 15 minutes, supporting rapid clinical decision-making and efficient patient workflow in point-of-care settings. Rapid diagnostic tests for chikungunya enable faster case identification and support timely clinical management.

Whole Blood / Serum / Plasma Compatibility – Flexible Sample Collection

The GHM Chikungunya IgG/IgM Rapid Test US is compatible with whole blood (venipuncture or fingerstick), serum, and plasma specimens, providing flexible sample collection options to accommodate different clinical protocols and patient needs. The test requires only a small sample volume, making it suitable for both clinic-based and field-based testing scenarios in resource-limited settings.

Clinical Utility – Aid for Diagnosis of Chikungunya Virus Infection

The GHM Chikungunya IgG/IgM Rapid Test US is intended for use as a screening test and as an aid in the diagnosis of infection with chikungunya virus. The test provides rapid serological diagnosis, enabling timely clinical decision-making and supporting patient management.

The dual-target design provides comprehensive diagnostic value. IgM antibodies are typically detectable within 3–5 days after symptom onset and may persist for several weeks to months, indicating acute or recent infection. IgG antibodies generally appear within 1–2 weeks after infection and persist for years, indicating past infection or immunity. The presence of both IgM and IgG may indicate a recent infection in a later stage. Because the clinical presentation of chikungunya overlaps significantly with dengue, Zika, and other arboviral diseases, laboratory confirmation through serological testing is essential for accurate differential diagnosis.

The test is particularly valuable in settings where rapid identification of chikungunya infection supports clinical management and public health intervention. Early detection of cases and timely access to appropriate medical care are essential for minimizing clinical complications and reducing mortality. The test is also suitable for use in decentralized testing environments where laboratory infrastructure may be limited.

High Accuracy – Trusted Clinical Performance

The GHM Chikungunya IgG/IgM Rapid Test US is designed to deliver reliable clinical performance with high sensitivity and specificity for both IgG and IgM targets. Clinical evaluation against reference methods has demonstrated strong performance, making this assay a valuable tool for point-of-care diagnostics when correctly used.

Performance characteristics based on evaluations of rapid chikungunya antibody tests. Published evaluations of rapid chikungunya tests in scenarios of Zika and dengue co-circulation in Brazil reported accuracy of 97.7%, with specificity and sensitivity of 97.9% and 96.8%, respectively, concluding that the rapid test has high performance for detecting CHIKV infection in co-circulation scenarios. Systematic reviews of rapid diagnostic tests for chikungunya have demonstrated that IgG detection tests achieve performance exceeding 93% regardless of the timing of sample collection. Detection is optimal when specimens are collected at appropriate time points during infection, and the test is best suited for use as an aid in the diagnosis of chikungunya in symptomatic patients.

ISO 13485 Certified – Quality and Safety Compliance

The VivaDiag product line is manufactured under an EN ISO 13485 certified quality management system, demonstrating compliance with stringent international standards for the design, development, manufacture, and distribution of in vitro diagnostic test kits and analyzers.

CE Marked – European Conformity

The GHM Chikungunya IgG/IgM Rapid Test US is CE marked for professional in vitro diagnostic use, demonstrating conformity with applicable European regulatory requirements for diagnostic medical devices.

Product Specifications

Why Clinical Professionals Choose Global Healthcare Medical

About Global Healthcare Medical

Global Healthcare Medical is dedicated to connecting healthcare providers, retailers, and distributors with high-quality medical devices designed for reliable performance. The GHM Chikungunya IgG/IgM Rapid Test US is part of our professional diagnostic line, developed to support accurate, efficient, and accessible point-of-care testing in clinical environments.

Our focus is on dependable performance, clear documentation, and responsive support for professional healthcare settings.